Co-Authors
This is a "connection" page, showing publications co-authored by Shaoguang Li and Lloyd Hutchinson.
Connection Strength
0.229
-
Zhang H, Peng C, Hu Y, Li H, Sheng Z, Chen Y, Sullivan C, Cerny J, Hutchinson L, Higgins A, Miron P, Zhang X, Brehm MA, Li D, Green MR, Li S. The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells. Nat Genet. 2012 Jul 15; 44(8):861-71.
Score: 0.099
-
Patel SA, Khedr S, Gordon CD, Nuvvula S, Littman N, Woda B, Hutchinson L, Li S, Xie Y, Selove W, Cerny J, Gerber JM. Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry. Cancer. 2025 Jul 01; 131(13):e35950.
Score: 0.061
-
Ma L, Pak ML, Ou J, Yu J, St Louis P, Shan Y, Hutchinson L, Li S, Brehm MA, Zhu LJ, Green MR. Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells. Proc Natl Acad Sci U S A. 2019 05 21; 116(21):10482-10487.
Score: 0.040
-
Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med. 2014 Sep 03; 6(252):252ra121.
Score: 0.029